YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

Patient 3

Before and After YUTIQ Treatment

VAImaging
Before YUTIQ Treatment20/25-
1.5-month follow-up after YUTIQ20/25+
9-month follow-up after YUTIQ20/32+

Patient’s vision has improved and is stable.

Continue to monitor for IOP elevations and inflammation recurrence.